Na Zhang, Xinyu Liu, Hui Wang, Wen Jiang, Xiaojing Zeng, Xiaoqing He, Qi Li, Xiaolin Wang, Yaorui Ye, Qianlong Zhang, Guowang Xu, Jun Zhang
{"title":"Early-pregnancy maternal metabolite signatures, genetic predisposition, and perinatal depressive symptom trajectories: A prospective birth cohort study.","authors":"Na Zhang, Xinyu Liu, Hui Wang, Wen Jiang, Xiaojing Zeng, Xiaoqing He, Qi Li, Xiaolin Wang, Yaorui Ye, Qianlong Zhang, Guowang Xu, Jun Zhang","doi":"10.1016/j.jad.2025.119768","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To identify early-pregnancy maternal circulating metabolites linked to perinatal depressive symptom trajectories, and to assess the potential role of genetic predisposition in these associations.</p><p><strong>Methods: </strong>We included 990 pregnant women from the Shanghai Birth Cohort, enrolled during early pregnancy. Maternal depressive symptoms were assessed during mid-pregnancy and at 42 days and 6 months postpartum using the Center for Epidemiologic Studies Depression Scale and Edinburgh Postnatal Depression Scale. A liquid chromatography-mass spectrometry metabolomics approach was employed to profile maternal serum metabolites. Perinatal depressive symptom trajectories were determined through group-based trajectory modelling, and metabolites were identified using elastic net and multinomial logistic regression.</p><p><strong>Results: </strong>Five perinatal depressive symptom trajectories were established: no symptoms (52.1 %, n = 516), low-stable (29.4 %, n = 291), resilient (10.9 %, n = 108), and recurrent (4.0 %, n = 40), and emergent (3.5 %, n = 35). Each unit increase in natural log-transformed FA 24: 0 (odds ratio (OR): 1.26, 95 % confidence interval (CI): 1.07-1.48) and 16,17-didehydropregnenolone (OR: 1.35, 95 % CI: 1.16-1.58) was associated with an elevated risk of a low-stable trajectory, while 16,17-didehydropregnenolone also linked to a higher risk of the recurrent trajectory (OR: 1.73, 95 % CI: 1.22-2.47). Conversely, metabolites such as 3beta,7alpha-Dihydroxy-5-cholestenoate and FA 6:0 were correlated with a reduced risk. No significant interactions were found between the identified metabolites and polygenetic risk.</p><p><strong>Conclusions: </strong>Early-pregnancy maternal metabolites were associated with perinatal depressive symptom trajectories, independent of genetic predisposition. These findings underscore the potential role of metabolic biomarkers in predicting perinatal depression. Future studies are warranted to replicate these findings in diverse cohorts and explore causality.</p>","PeriodicalId":14963,"journal":{"name":"Journal of affective disorders","volume":" ","pages":"119768"},"PeriodicalIF":4.9000,"publicationDate":"2025-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of affective disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jad.2025.119768","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To identify early-pregnancy maternal circulating metabolites linked to perinatal depressive symptom trajectories, and to assess the potential role of genetic predisposition in these associations.
Methods: We included 990 pregnant women from the Shanghai Birth Cohort, enrolled during early pregnancy. Maternal depressive symptoms were assessed during mid-pregnancy and at 42 days and 6 months postpartum using the Center for Epidemiologic Studies Depression Scale and Edinburgh Postnatal Depression Scale. A liquid chromatography-mass spectrometry metabolomics approach was employed to profile maternal serum metabolites. Perinatal depressive symptom trajectories were determined through group-based trajectory modelling, and metabolites were identified using elastic net and multinomial logistic regression.
Results: Five perinatal depressive symptom trajectories were established: no symptoms (52.1 %, n = 516), low-stable (29.4 %, n = 291), resilient (10.9 %, n = 108), and recurrent (4.0 %, n = 40), and emergent (3.5 %, n = 35). Each unit increase in natural log-transformed FA 24: 0 (odds ratio (OR): 1.26, 95 % confidence interval (CI): 1.07-1.48) and 16,17-didehydropregnenolone (OR: 1.35, 95 % CI: 1.16-1.58) was associated with an elevated risk of a low-stable trajectory, while 16,17-didehydropregnenolone also linked to a higher risk of the recurrent trajectory (OR: 1.73, 95 % CI: 1.22-2.47). Conversely, metabolites such as 3beta,7alpha-Dihydroxy-5-cholestenoate and FA 6:0 were correlated with a reduced risk. No significant interactions were found between the identified metabolites and polygenetic risk.
Conclusions: Early-pregnancy maternal metabolites were associated with perinatal depressive symptom trajectories, independent of genetic predisposition. These findings underscore the potential role of metabolic biomarkers in predicting perinatal depression. Future studies are warranted to replicate these findings in diverse cohorts and explore causality.
期刊介绍:
The Journal of Affective Disorders publishes papers concerned with affective disorders in the widest sense: depression, mania, mood spectrum, emotions and personality, anxiety and stress. It is interdisciplinary and aims to bring together different approaches for a diverse readership. Top quality papers will be accepted dealing with any aspect of affective disorders, including neuroimaging, cognitive neurosciences, genetics, molecular biology, experimental and clinical neurosciences, pharmacology, neuroimmunoendocrinology, intervention and treatment trials.